Pattern of Cerebral Hypoperfusion in Alzheimer Disease and Mild Cognitive Impairment Measured with Arterial Spin-labeling MR Imaging: Initial Experience

PURPOSE: To prospectively determine if pulsed arterial spin-labeling perfusion magnetic resonance (MR) imaging depicts regional cerebral hypoperfusion in subjects with Alzheimer disease (AD) and mild cognitive impairment (MCI), compared with perfusion in cognitively normal (CN) subjects, that is consistent with results of fluorodeoxyglucose (FDG) positron emission tomography (PET) and hexamethylpropyleneamine oxime (HMPAO) single photon emission computed tomography (SPECT) studies of similar populations.

MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained. Twenty subjects with AD (13 men, seven women; mean age, 72.9 years), 18 with MCI (nine men, nine women; mean age, 73.3 years), and 23 CN subjects (10 men, 13 women; mean age, 72.9 years) underwent arterial spin-labeling and volumetric T1-weighted structural MR imaging. Perfusion images were coregistered to structural images, corrected for partial volume effects (PVEs) with information from the structural image to determine tissue content of perfusion voxels, and normalized to a study-specific template. Analyses of perfusion differences between groups, with and without corrections for PVEs, were performed on a voxel-by-voxel basis with a one-tailed fixed-effects analysis of covariance model adjusted for age. In addition, tests were performed with and without accounting for global perfusion.

RESULTS: The AD group showed significant regional hypoperfusion, compared with the CN group, in the right inferior parietal cortex extending into the bilateral posterior cingulate gyri (P < .001), bilateral superior and middle frontal gyri (P < .001), and left inferior parietal lobe (P = .007). When PVEs from underlying cortical gray matter atrophy were accounted for, the AD group still showed hypoperfusion in the right inferior parietal lobe extending into the bilateral posterior cingulate gyri (P < .001) and left (P = .003) and right (P = .012) middle frontal gyri. With a more liberal voxel-level threshold of P < .01, the MCI group showed significant regional hypoperfusion relative to the CN group in the inferior right parietal lobe (P = .046), similar to the region of greatest significance in the AD group.

CONCLUSION: Arterial spin-labeling MR imaging showed regional hypoperfusion with AD, in brain regions similar to those seen in FDG PET and HMPAO SPECT studies of similar populations; this hypoperfusion persists after accounting for underlying cortical gray matter atrophy.

© RSNA, 2005


  • 1 Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18:351-357. Crossref, MedlineGoogle Scholar
  • 2 Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer’s disease. J Neural Transm Suppl 1998; 53:127-140. Crossref, MedlineGoogle Scholar
  • 3 Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 2003; 17(suppl 4):S105-S113. Crossref, MedlineGoogle Scholar
  • 4 Mielke R, Kessler J, Szelies B, Herholz K, Wienhard K, Heiss WD. Normal and pathological aging: findings of positron-emission-tomography. J Neural Transm 1998; 105:821-837. Crossref, MedlineGoogle Scholar
  • 5 Jagust WJ. Neuroimaging in dementia. Neurol Clin 2000; 18:885-902. Crossref, MedlineGoogle Scholar
  • 6 Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003; 226:315-336. LinkGoogle Scholar
  • 7 Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995; 273:942-947. Crossref, MedlineGoogle Scholar
  • 8 Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334:752-758. Crossref, MedlineGoogle Scholar
  • 9 Johnson KA, Lopera F, Jones K, et al. Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology 2001; 56:1545-1551. Crossref, MedlineGoogle Scholar
  • 10 Kennedy AM, Frackowiak RS, Newman SK, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease. Neurosci Lett 1995; 186:17-20. Crossref, MedlineGoogle Scholar
  • 11 Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer’s disease using SPECT. Neurology 1998; 50:1563-1571. Crossref, MedlineGoogle Scholar
  • 12 Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer’s disease using brain perfusion SPECT. J Nucl Med 2000; 41:1155-1162. MedlineGoogle Scholar
  • 13 Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging 2000; 21:289-292. Crossref, MedlineGoogle Scholar
  • 14 El Fakhri G, Kijewski MF, Johnson KA, et al. MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol 2003; 60:1066-1072. Crossref, MedlineGoogle Scholar
  • 15 Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport 2001; 12:851-855. Crossref, MedlineGoogle Scholar
  • 16 Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 2003; 60:1374-1377. Crossref, MedlineGoogle Scholar
  • 17 Huang C, Wahlund LO, Almkvist O, et al. Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage 2003; 19:1137-1144. Crossref, MedlineGoogle Scholar
  • 18 Roberts DA, Detre JA, Bolinger L, Insko EK, Leigh JJ. Quantitative magnetic resonance imaging of human brain perfusion at 1.5 T using steady-state inversion of arterial water. Proc Natl Acad Sci USA 1994; 91:33-37. Crossref, MedlineGoogle Scholar
  • 19 Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? implications for PET and fMRI. Neuroimage 1995; 2:148-156. Crossref, MedlineGoogle Scholar
  • 20 Detre JA, Alsop DC. Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. Eur J Radiol 1999; 30:115-124. Crossref, MedlineGoogle Scholar
  • 21 Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer’s disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000; 47:93-100. Crossref, MedlineGoogle Scholar
  • 22 Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer’s disease. Neurology 1998; 50:1585-1593. Crossref, MedlineGoogle Scholar
  • 23 Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer’s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996; 47:454-461. Crossref, MedlineGoogle Scholar
  • 24 Meltzer CC, Cantwell MN, Greer PJ, et al. Does cerebral blood flow decline in healthy aging? a PET study with partial-volume correction. J Nucl Med 2000; 41:1842-1848. MedlineGoogle Scholar
  • 25 Matsuda H, Kanetaka H, Ohnishi T, et al. Brain SPET abnormalities in Alzheimer’s disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 2002; 29:1502-1505. Crossref, MedlineGoogle Scholar
  • 26 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198. Crossref, MedlineGoogle Scholar
  • 27 Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test (CVLT) San Antonio, Tex: Psychological Corporation, 2000. Google Scholar
  • 28 Lezak MD. Neuropsychological assessment 3rd ed. New York, NY: Oxford University Press, 1995. Google Scholar
  • 29 Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414. Crossref, MedlineGoogle Scholar
  • 30 Pfeffer RI, Kurosaki TT, Harrah CH, Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982; 37:323-329. Crossref, MedlineGoogle Scholar
  • 31 Criteria for the clinical diagnosis of Alzheimer’s disease: excerpts from the NINCDS-ADRDA Work Group report.J Am Geriatr Soc1985; 33:2-3. Crossref, MedlineGoogle Scholar
  • 32 Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308. Crossref, MedlineGoogle Scholar
  • 33 Jahng GH, Zhu XP, Matson GB, Weiner MW, Schuff N. Improved perfusion-weighted MRI by a novel double inversion with proximal labeling of both tagged and control acquisitions. Magn Reson Med 2003; 49:307-314. Crossref, MedlineGoogle Scholar
  • 34 Luh WM, Wong EC, Bandettini PA, Hyde JS. QUIPSS II with thin-slice TI1 periodic saturation: a method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling. Magn Reson Med 1999; 41:1246-1254. Crossref, MedlineGoogle Scholar
  • 35 Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of aging in 465 normal adult human brains. Neuroimage 2001; 14:21-36. Crossref, MedlineGoogle Scholar
  • 36 Meltzer CC, Leal JP, Mayberg HS, Wagner HN, Jr, Frost JJ. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 1990; 14:561-570. Crossref, MedlineGoogle Scholar
  • 37 Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992; 12:571-583. Crossref, MedlineGoogle Scholar
  • 38 Salmond CH, Ashburner J, Vargha-Khadem F, Gadian DG, Friston KJ. Detecting bilateral abnormalities with voxel-based morphometry. Hum Brain Mapp 2000; 11:223-232. Crossref, MedlineGoogle Scholar
  • 39 Bradley KM, O’Sullivan VT, Soper ND, et al. Cerebral perfusion SPECT correlated with Braak pathological stage in Alzheimer’s disease. Brain 2002; 125:1772-1781. Crossref, MedlineGoogle Scholar
  • 40 Lee YC, Liu RS, Liao YC, et al. Statistical parametric mapping of brain SPECT perfusion abnormalities in patients with Alzheimer’s disease. Eur Neurol 2003; 49:142-145. Crossref, MedlineGoogle Scholar
  • 41 Matsuda H, Kitayama N, Ohnishi T, et al. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer’s disease. J Nucl Med 2002; 43:304-311. MedlineGoogle Scholar
  • 42 Meguro K, LeMestric C, Landeau B, Desgranges B, Eustache F, Baron JC. Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer’s disease: a PET/MRI correlative study. J Neurol Neurosurg Psychiatry 2001; 71:315-321. Crossref, MedlineGoogle Scholar
  • 43 Varma AR, Adams W, Lloyd JJ, et al. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer’s disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 2002; 105:261-269. Crossref, MedlineGoogle Scholar
  • 44 Chetelat G, Desgranges B, de la Sayette V, et al. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 2003; 126:1955-1967. Crossref, MedlineGoogle Scholar
  • 45 Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179:52-76. MedlineGoogle Scholar

Article History

Published in print: Mar 2005